XML 32 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
BUSINESS SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
BUSINESS SEGMENT INFORMATION
BUSINESS SEGMENT INFORMATION
The Company's DIS business provides insights through clinical testing and related services to patients, physicians, hospitals, ACOs, IDNs, health plans, employers and others. The Company is the world's leading provider of diagnostic information services, which includes providing clinical testing services such as routine (including drugs-of-abuse) testing, advanced testing solutions (including gene-based and esoteric testing), and anatomic pathology services, as well as related services and insights. The DIS business accounted for greater than 90% of net revenues in 2016 and 2015.

All other operating segments include the Company's DS businesses, which consists of its risk assessment services, healthcare information technology, diagnostic products (prior to May 13, 2016), and clinical trials testing (prior to July 1, 2015) businesses. The Company's DS businesses offer a variety of solutions for life insurers, healthcare providers and others.

In addition to the sale of Focus Diagnostics (see Note 6), the Company wound down its Celera products business, which did not have a material impact on the Company's consolidated financial statements. As a result of these transactions, the Company has disposed of its diagnostics products business.
        
As of September 30, 2016, substantially all of the Company’s services are provided within the United States, and substantially all of the Company’s assets are located within the United States.

The following table is a summary of segment information for the three and nine months ended September 30, 2016 and 2015. Segment asset information is not presented since it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses and the gains on disposition of businesses associated with the sale of Focus Diagnostics (see Note 6) and the contribution of the Company's clinical trials testing business to the Q2 Solutions joint venture in the third quarter of 2015. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the consolidated financial statements contained in the Company’s 2015 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net revenues:
 

 
 

 
 

 
 

DIS business
$
1,800

 
$
1,764

 
$
5,365

 
$
5,227

All other operating segments
85

 
116

 
289

 
417

Total net revenues
$
1,885

 
$
1,880

 
$
5,654

 
$
5,644

 
 
 
 
 
 
 
 
Operating earnings (loss):
 

 
 

 
 

 
 

DIS business
$
329

 
$
294

 
$
935

 
$
838

All other operating segments
12

 
30

 
50

 
86

General corporate activities
(19
)
 
307

 
16

 
236

Total operating income
322

 
631

 
1,001

 
1,160

Non-operating expenses, net
(33
)
 
(39
)
 
(157
)
 
(263
)
Income before income taxes and equity in earnings of equity method investees
289

 
592

 
844

 
897

Income tax expense
(95
)
 
(239
)
 
(345
)
 
(359
)
Equity in earnings of equity method investees, net of taxes
11

 
1

 
30

 
15

Net income
205

 
354

 
529

 
553

Less: Net income attributable to noncontrolling interests
13

 
12

 
39

 
32

Net income attributable to Quest Diagnostics
$
192

 
$
342

 
$
490

 
$
521